These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22689800)

  • 1. Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
    Stuplich M; Hadizadeh DR; Kuchelmeister K; Scorzin J; Filss C; Langen KJ; Schäfer N; Mack F; Schüller H; Simon M; Glas M; Pietsch T; Urbach H; Herrlinger U
    J Clin Oncol; 2012 Jul; 30(21):e180-3. PubMed ID: 22689800
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
    Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE
    J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant temozolomide: how long and how much?
    Franceschi E; Tosoni A; Brandes AA
    Expert Rev Anticancer Ther; 2008 May; 8(5):663-5. PubMed ID: 18471038
    [No Abstract]   [Full Text] [Related]  

  • 4. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
    Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH
    Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
    Chamberlain MC; Glantz MJ; Chalmers L; Van Horn A; Sloan AE
    J Neurooncol; 2007 Mar; 82(1):81-3. PubMed ID: 16944309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
    Herrlinger U; Rieger J; Koch D; Loeser S; Blaschke B; Kortmann RD; Steinbach JP; Hundsberger T; Wick W; Meyermann R; Tan TC; Sommer C; Bamberg M; Reifenberger G; Weller M
    J Clin Oncol; 2006 Sep; 24(27):4412-7. PubMed ID: 16983109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-based study of pseudoprogression after chemoradiotherapy in GBM.
    Roldán GB; Scott JN; McIntyre JB; Dharmawardene M; de Robles PA; Magliocco AM; Yan ES; Parney IF; Forsyth PA; Cairncross JG; Hamilton MG; Easaw JC
    Can J Neurol Sci; 2009 Sep; 36(5):617-22. PubMed ID: 19831132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
    Malkoun N; Fotso MJ; Cartier L; Forest F; Auberdiac P; Chargari C; Thorin J; Pacaut C; Peoc'h M; Nuti C; Schmitt T; Magné N
    Cancer Radiother; 2011 Jun; 15(3):202-7. PubMed ID: 21450506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
    Piroth MD; Gagel B; Pinkawa M; Stanzel S; Asadpour B; Eble MJ
    Strahlenther Onkol; 2007 Dec; 183(12):695-702. PubMed ID: 18040615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
    Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
    J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
    Cahill DP; Codd PJ; Batchelor TT; Curry WT; Louis DN
    Clin Neurosurg; 2008; 55():165-71. PubMed ID: 19248684
    [No Abstract]   [Full Text] [Related]  

  • 15. Temozolomide in glioblastoma multiforme of the elderly.
    Brandes AA; Vastola F; Basso U; Pasetto LM; Ermani M; Berti F; Rotilio A; Amistà P; Scienza R; Monfardini S
    Tumori; 2002; 88(1 Suppl 1):S69-70. PubMed ID: 11989929
    [No Abstract]   [Full Text] [Related]  

  • 16. [Temozolomide in patients with a glioblastoma multiforme: new developments].
    Bromberg JE; Postma TJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
    Peca C; Pacelli R; Elefante A; Del Basso De Caro ML; Vergara P; Mariniello G; Giamundo A; Maiuri F
    Clin Neurol Neurosurg; 2009 May; 111(4):331-4. PubMed ID: 19117668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
    Levin VA
    Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
    Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
    Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of glioblastoma in elderly patients: an overview of current treatments and future perspective.
    Lanzetta G; Minniti G
    Tumori; 2010; 96(5):650-8. PubMed ID: 21302607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.